After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
Patents expiring between 2025-2030 will put more than $200 billion of Big Pharma’s revenues at risk, thus positioning them to fill their pipelines through acquisitions.
Drug giant J&J needs to plug a revenue hole that’s approaching in 2025, when its top seller Stelara for psoriasis is expected to face generic competitors.
January 8, 2024
Join our Membership
Join the Merger & Acquisitions community to access premium content and exclusive member-only benefits.
Drugmakers have been focused on buying late-stage assets with larger revenue potential to replace older blockbuster drugs that have fallen out of favor.